| Literature DB >> 20130789 |
Joshua J Coon1, Petra Zürbig, Mohammed Dakna, Anna F Dominiczak, Stéphane Decramer, Danilo Fliser, Moritz Frommberger, Igor Golovko, David M Good, Stefan Herget-Rosenthal, Joachim Jankowski, Bruce A Julian, Markus Kellmann, Walter Kolch, Ziad Massy, Jan Novak, Kasper Rossing, Joost P Schanstra, Eric Schiffer, Dan Theodorescu, Raymond Vanholder, Eva M Weissinger, Harald Mischak, Philippe Schmitt-Kopplin.
Abstract
Owing to its availability, ease of collection, and correlation with pathophysiology of diseases, urine is an attractive source for clinical proteomics. However, many proteomic studies have had only limited clinical impact, due to factors such as modest numbers of subjects, absence of disease controls, small numbers of defined biomarkers, and diversity of analytical platforms. Therefore, it is difficult to merge biomarkers from different studies into a broadly applicable human urinary proteome database. Ideally, the methodology for defining the biomarkers should combine a reasonable analysis time with high resolution, thereby enabling the profiling of adequate samples and recognition of sufficient features to yield robust diagnostic panels. Capillary electrophoresis coupled to mass spectrometry (CE-MS), which was used to analyze urine samples from healthy subjects and patients with various diseases, is a suitable approach for this task. The database of these datasets compiled from the urinary peptides enabled the diagnosis, classification, and monitoring of a wide range of diseases. CE-MS exhibits excellent performance for biomarker discovery and allows subsequent biomarker sequencing independent of the separation platform. This approach may elucidate the pathogenesis of many diseases, and better define especially renal and urological disorders at the molecular level.Entities:
Year: 2008 PMID: 20130789 PMCID: PMC2815342 DOI: 10.1002/prca.200800024
Source DB: PubMed Journal: Proteomics Clin Appl ISSN: 1862-8346 Impact factor: 3.494